Radiation poisoning is one of the few medical emergencies in which the timeline is set by physics, not by clinical decision-making. The dose is delivered in seconds. The body's response is fixed by biology. The window in which a medical countermeasure changes the outcome is, in some categories, less than two hours.
That timeline determines what a country must hold on its shelves before an event occurs. A national stockpile assembled after the first symptoms appear is too late. A protocol drafted during the response is the wrong document at the wrong moment.
This article sets out, in procurement-relevant detail, what acute radiation syndrome looks like, when symptoms appear at each dose, what the treatment protocols actually require, and which medicines have to be pre-positioned to give clinicians anything to work with. The intent is not to train physicians — there are dedicated clinical references for that — but to give procurement officers, medical-supply planners, and ministry stockpile managers the context they need to map symptom severity to the medicines a national reserve must contain.
Why Ministries — Not Consumers — Should Understand ARS First
Most public-facing material on radiation poisoning is written for either patients undergoing therapeutic radiation or for general consumer education. Major clinical and consumer-health publishers all rank highly for "radiation sickness" and "acute radiation syndrome" — and most frame the topic for an individual reader.
That framing is not useful to a procurement officer. The procurement question is not "what will I feel" but "what must we have ready, in what quantity, with what shelf life, for the population we are responsible for." The clinical literature exists. What is missing in the public domain is the bridge from clinical phase to medical-countermeasure SKU on the warehouse shelf.
That bridge is the focus of this article. The clinical authority is anchored to the U.S. Centers for Disease Control and Prevention's Radiation Emergency Medical Management (REMM) platform, the Armed Forces Radiobiology Research Institute (AFRRI) handbook on Medical Management of Radiological Casualties (4th edition, July 2013), and the World Health Organization's 2023 stockpile policy.
Acute Radiation Syndrome: Three Sub-Syndromes, Three Thresholds
Acute Radiation Syndrome (ARS) is not a single illness. It is a sequence of three overlapping clinical syndromes, each with its own dose threshold, time course, and prognosis. The CDC's clinical guidance for ARS sets the boundaries clearly.
- Mild presentations from approximately 0.3 Gy
- Moderate to severe presentations: 0.7 Gy to 10 Gy
- Principal injury: bone marrow suppression — white-cell, red-cell, and platelet precursors are killed
- Clinical danger window: 2 to 4 weeks post-exposure (overwhelming infection and hemorrhage risk)
- Most ARS deaths in survivable dose ranges trace to this window
- Begins to overlap with H-ARS at approximately 6 Gy
- Becomes the dominant clinical picture at doses of 10 Gy and above
- Radiation kills the rapidly dividing cells of the intestinal lining
- Result: severe diarrhea, fluid loss, bacterial translocation, sepsis
- Without intensive care, mortality is near total
- Appears at doses above 20 Gy; dominates above 50 Gy
- Presents within minutes to hours: hypotension, cerebral edema, seizures, circulatory collapse
- No medical countermeasure meaningfully alters the outcome
- Death is expected within three days
The doses at which each sub-syndrome dominates are not arbitrary numbers. They are the clinical anchors a stockpile must address. A national reserve designed for the survivable range — 0.7 Gy to 10 Gy — must be built around the medicines that change H-ARS outcomes. Above 10 Gy, supportive care extends life; it does not save it. Above 20 Gy, the best-equipped stockpile in the world cannot.
The Four Phases of Acute Radiation Syndrome
Within each sub-syndrome, ARS unfolds in four distinct phases. The REMM time-phases framework, used by U.S. federal responders, is the standard reference.
- Onset within minutes to 48 hours of exposure
- Dominant symptom: nausea and vomiting
- Time-to-emesis is a reliable triage proxy for absorbed dose
- Onset within 1 hour suggests dose above 4 Gy
- Onset 1–2 hours suggests roughly 2–4 Gy
- Onset later than 4 hours typically corresponds to milder exposure under 2 Gy
- Acute symptoms resolve; patient may feel well for hours, days, or up to three weeks
- Latent phase is dose-inverse — higher dose, shorter latent period, worse eventual outcome
- A patient who appears recovered at day 3 is not recovered
- This is the calm before manifest illness
- For H-ARS in the survivable range: 2-to-4-week neutrophil nadir window
- Highest infection risk; requires broad-spectrum antibiotics, antifungals, antivirals
- Requires irradiated leukocyte-reduced blood products
- For GI-ARS: manifest phase begins around 5–10 days with severe enteritis
- For CNS-ARS: manifest phase is the entire clinical course
- Below 4 Gy with adequate supportive care: full recovery is possible
- LD50/60 with no medical care: approximately 3.5 to 4.0 Gy
- LD50/60 with antibiotics and transfusion support: 4.5 to 7 Gy
- LD50/60 with intensive care including cytokines: 7 to 9 Gy
- Above 10 to 12 Gy whole-body: survival is essentially zero regardless of intervention
Symptoms by Dose Tier — And What Each Demands From Your Stockpile
The stockpile design question becomes concrete when symptoms are mapped to dose ranges and to the medicines required at each level. The table below summarises the clinical picture and procurement implication for each band.
| Dose Range | Clinical Picture | Stockpile Requirement |
|---|---|---|
| 1 to 2 Gy (mild) | Approximately 50 percent of patients develop nausea and vomiting within 6 hours. Latent phase 1 to 3 weeks. Mild bone marrow suppression. Most patients recover with outpatient observation. | Oral antiemetics, antibiotics for incidental infection during the cytopenic window, basic blood-product access. |
| 2 to 4 Gy (moderate) | Vomiting within 1 to 2 hours. Neutrophil nadir at 2 to 3 weeks. Treatment is mandatory: hospitalisation, broad-spectrum antibiotics, blood products, supportive care. Survival without treatment is uncertain; with treatment, very high. | Parenteral antibiotics, irradiated leukocyte-reduced blood products, fluids, electrolytes, antiemetics, reverse-isolation capacity. |
| 4 to 6 Gy (severe) | Emesis within an hour. Severe pancytopenia. Mortality without aggressive care is approximately 50 percent. | As above, plus FDA-approved myeloid cytokines for hematopoietic ARS — filgrastim (2015), pegfilgrastim (2015), and sargramostim (2018), approved under the FDA Animal Rule. |
| 6 to 8 Gy (very severe) | Emesis within 30 minutes. GI involvement begins to dominate. Mortality is high even with intensive care. | As above, plus large-volume fluid resuscitation, total parenteral nutrition where available, decision-pathways for hematopoietic stem cell transplantation in selected cases. |
| Above 8 Gy (lethal) | Multi-organ failure. CV/CNS symptoms appear. | Stockpile shifts to palliative care: opioid analgesics, sedation, antiemetics. Documentation and triage protocols matter as much as medication. |
A national stockpile that holds antiemetics and analgesics but lacks cytokines, antibiotics in surge quantities, and irradiated blood products is a stockpile prepared only for the lowest-dose tier. The doses that produce the highest political and clinical pressure — 2 to 6 Gy — require everything in the list.
Cutaneous Radiation Injury and Chronic Effects
Not all radiation injuries are systemic. Localised exposure — particularly from contact with industrial sources, medical isotopes, or fallout deposited on skin — produces cutaneous radiation injury (CRI). The threshold is approximately 2 Gy local dose.
The clinical pattern mirrors ARS in miniature. Prodromal erythema appears within hours. A latent period of days to weeks follows. The manifest phase produces deeper erythema, dry and moist desquamation, and ulceration. Above approximately 10 Gy local dose, late effects emerge over months to years: telangiectasia, dermal atrophy, fibrosis, chronic ulcer recurrence, and necrosis.
CRI is a stockpile category in its own right. It requires sterile dressings, debridement supplies, topical antibiotics, advanced wound-care products, and where the burden is significant, plastic-surgery referral capacity. Most national stockpiles incorporate CRI requirements into broader trauma-supply categories. Procurement officers should confirm that the trauma reserve is sized for the radiological-incident scenario, not only for conventional mass-casualty events.
The WHO-Recommended National Stockpile
The World Health Organization's January 2023 publication "National Stockpiles for Radiological and Nuclear Emergencies: Policy Advice" (ISBN 978-92-4-006787-5) sets the formulary that every member state is expected to hold. The list reflects the protocol above and is the procurement benchmark institutional buyers should anchor their emergency preparedness reserve against.
- Stable iodine — Potassium Iodide and Potassium Iodate, in age-appropriate dose tiers (16 mg neonates, 32 mg infants, 65 mg children, 130 mg adolescents/adults)
- Prussian Blue (ferric hexacyanoferrate) for cesium and thallium decorporation
- Calcium-DTPA and zinc-DTPA for transuranic decorporation (plutonium, americium, curium)
- Myeloid cytokines for hematopoietic ARS (filgrastim, pegfilgrastim, sargramostim)
- Antiemetics, antidiarrheals, and supportive medications
- Broad-spectrum antibiotics in surge quantities for febrile neutropenia and post-exposure prophylaxis
- Blood products with capacity for irradiated leukocyte-reduced supply
Both Potassium Iodide and Prussian Blue appear on the WHO Model List of Essential Medicines. Prussian Blue's listing dates to 1989, despite its orphan-drug status — a status that reflects the rarity of cesium-contamination events, not a lower priority. The WHO position is unambiguous: every country should hold both, alongside the broader formulary.
How Golden Hour Pharma Supports the Decorporation Pillar
Golden Hour Pharma supplies the three core pillars of the radiological decorporation stockpile that the WHO formulary recommends: Potassium Iodide in 32 mg, 65 mg, and 130 mg strengths, covering the infant, paediatric, and adult tiers; Potassium Iodate as a long-shelf-life thyroid-blocking alternative for tropical climates and humid storage environments; and Prussian Blue (ferric hexacyanoferrate) for cesium and thallium decorporation. Each is supplied with WHO-aligned cGMP manufacturing, batch validation, certificate of analysis, and dossier readiness for institutional regulatory review.
The cytokines, transuranic chelators, irradiated blood-product capacity, and broad-spectrum antibiotic categories require separate procurement pathways and, in many jurisdictions, separate regulatory approvals. Golden Hour Pharma's role is the decorporation pillar — the medicines a stockpile cannot reasonably substitute around, and which require qualified manufacturer relationships and validated supply chains to procure at scale.
For procurement teams reviewing radiological-readiness stockpile composition for fiscal year 2026, the practical next step is a category-by-category audit of existing inventory against the WHO formulary, with documentation of strength, lot, expiry, and dose-tier coverage for each entry. Where gaps appear in the decorporation pillar, institutional buyers can request a procurement dossier to confirm specifications, lead times, and certificate-of-analysis support.
Radiation poisoning is unusual in modern medicine because the clinical timeline is set before the patient reaches the hospital. The window in which Potassium Iodide changes a thyroid outcome is hours. The window in which decontamination prevents internal contamination is minutes.
The window in which a national stockpile is built — and stocked, and rotated, and ready — is years. Golden Hour Pharma supports institutional procurement teams reviewing radiological-readiness stockpile composition with WHO-aligned supply, complete documentation, and reliable delivery across 30+ countries.
We are not just a company … we are a force
Ready when it matters most.